Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of Adaptive Immunological Signature in the More Aggressive Histological Types

Immunohistochemistry in Peritoneal Mesothelioma: A Single-Center Experience of 244 Cases

(2018) Radhika Theresa Tandon et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Polycomb Repressive Complex 2-Mediated Chromatin Repression Guides Effector CD8 + T Cell Terminal Differentiation and Loss of Multipotency

(2017) Simon M. Gray et al.   IMMUNITY

Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib Treatment

(2017) Marcella Tazzari et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

(2017) Michele Maio et al.   LANCET ONCOLOGY

Malignant Mesothelioma Effusions Are Infiltrated by CD3 + T Cells Highly Expressing PD-L1 and the PD-L1 + Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti–PD-L1 Antibody Avelumab

(2016) Swati Khanna et al.   Journal of Thoracic Oncology

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

Epithelioid peritoneal mesothelioma: a hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition framework

(2016) Fabio Bozzi et al.   Oncotarget

Dysregulation of peritoneal cavity B1a cells and murine primary biliary cholangitis

(2016) Yan-Qing Yang et al.   Oncotarget

Interferon Regulatory Factor 4 controls TH1 cell effector function and metabolism

(2016) Justus Mahnke et al.   Scientific Reports

Regulation of T Cell Differentiation and Function by EZH2

(2016) Theodoros Karantanos et al.   Frontiers in Immunology

Malignant Peritoneal Mesothelioma: Characterization of the Inflammatory Response in the Tumor Microenvironment

(2015) Sean Judge et al.   ANNALS OF SURGICAL ONCOLOGY

Characteristics of natural antibody-secreting cells

(2015) Hannah P. Savage et al.   Annals of the New York Academy of Sciences

PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer

(2015) Nisha Nagarsheth et al.   CANCER RESEARCH

Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses

(2015) Nikhil S. Joshi et al.   IMMUNITY

Regulatory B Cells: Origin, Phenotype, and Function

(2015) Elizabeth C. Rosser et al.   IMMUNITY

Tertiary Lymphoid Tissue in the Tumor Microenvironment: From Its Occurrence to Immunotherapeutic Implications

(2015) Giuseppe Di Caro et al.   INTERNATIONAL REVIEWS OF IMMUNOLOGY

Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy

(2015) Dongjun Peng et al.   NATURE

PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors

(2014) Alena Gros et al.   JOURNAL OF CLINICAL INVESTIGATION

CD209+ Macrophages Mediate Host Defense against Propionibacterium acnes

(2014) P. T. Liu et al.   JOURNAL OF IMMUNOLOGY

Ezh2 Regulates Transcriptional and Posttranslational Expression of T-bet and Promotes Th1 Cell Responses Mediating Aplastic Anemia in Mice

(2014) Q. Tong et al.   JOURNAL OF IMMUNOLOGY

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Should EMT of Cancer Cells Be Understood as Epithelial-Myeloid Transition?

(2014) Henning M. Schramm   Journal of Cancer

Tertiary lymphoid tissue

(2014) Giuseppe Di Caro et al.   OncoImmunology

EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation

(2013) Wendy Béguelin et al.   CANCER CELL

Interferon Regulatory Factor 4 Sustains CD8+ T Cell Expansion and Effector Differentiation

(2013) Shuyu Yao et al.   IMMUNITY

The Polycomb Protein Ezh2 Regulates Differentiation and Plasticity of CD4+ T Helper Type 1 and Type 2 Cells

(2013) Damon J. Tumes et al.   IMMUNITY

In Vivo T Cell Activation Induces the Formation of CD209+ PDL-2+ Dendritic Cells

(2013) Matthew G. Davidson et al.   PLoS One

Immunity and malignant mesothelioma: From mesothelial cell damage to tumor development and immune response-based therapies

(2012) Valerio Izzi et al.   CANCER LETTERS

Epithelial immune cell-like transition (EIT): A proposed transdifferentiation process underlying immune-suppressive activity of epithelial cancers

(2012) Stephen Yiu Chuen Choi et al.   DIFFERENTIATION

Asbestos-Induced Cellular and Molecular Alteration of Immunocompetent Cells and Their Relationship with Chronic Inflammation and Carcinogenesis

(2012) Hidenori Matsuzaki et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Human Renal Cell Carcinoma Induces a Dendritic Cell Subset That Uses T-Cell Crosstalk for Tumor-Permissive Milieu Alterations

(2011) Ainhoa-M. Figel et al.   AMERICAN JOURNAL OF PATHOLOGY

CD19+CD24hiCD38hi B Cells Exhibit Regulatory Capacity in Healthy Individuals but Are Functionally Impaired in Systemic Lupus Erythematosus Patients

(2010) Paul A. Blair et al.   IMMUNITY

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

(2009) M. Ahmadzadeh et al.   BLOOD

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

(2009) Loise M. Francisco et al.   JOURNAL OF EXPERIMENTAL MEDICINE